Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Rating of “Hold” by Brokerages

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have earned a consensus recommendation of “Hold” from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $4.25.

A number of equities research analysts have recently commented on the stock. HC Wainwright reduced their price objective on shares of Inovio Pharmaceuticals from $3.00 to $2.50 and set a “neutral” rating on the stock in a research note on Monday, June 1st. Weiss Ratings raised shares of Inovio Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 16th. Wall Street Zen lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Inovio Pharmaceuticals in a research note on Friday, March 13th.

Inovio Pharmaceuticals Stock Performance

NASDAQ:INO opened at $1.13 on Wednesday. The firm’s fifty day moving average is $1.20 and its 200-day moving average is $1.53. Inovio Pharmaceuticals has a 52 week low of $1.03 and a 52 week high of $2.98. The firm has a market cap of $92.97 million, a P/E ratio of -0.78 and a beta of 1.49.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. As a group, sell-side analysts anticipate that Inovio Pharmaceuticals will post -0.97 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Janus Henderson Group PLC boosted its stake in Inovio Pharmaceuticals by 1.3% during the fourth quarter. Janus Henderson Group PLC now owns 3,308,406 shares of the biopharmaceutical company’s stock worth $5,773,000 after acquiring an additional 42,146 shares in the last quarter. Vanguard Group Inc. boosted its stake in Inovio Pharmaceuticals by 35.0% during the third quarter. Vanguard Group Inc. now owns 2,712,872 shares of the biopharmaceutical company’s stock worth $6,348,000 after acquiring an additional 703,727 shares in the last quarter. Boxer Capital Management LLC bought a new position in Inovio Pharmaceuticals during the third quarter worth $5,382,000. Millennium Management LLC boosted its stake in Inovio Pharmaceuticals by 468.7% during the third quarter. Millennium Management LLC now owns 1,972,518 shares of the biopharmaceutical company’s stock worth $4,616,000 after acquiring an additional 1,625,653 shares in the last quarter. Finally, Eversept Partners LP bought a new position in Inovio Pharmaceuticals during the first quarter worth $1,802,000. 26.79% of the stock is owned by institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.